A Study of TQ-B3525 on Tolerance and Pharmacokinetics

A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Inclusion Criteria:

• Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
• ECOG PS≤1
• Adequate blood cell counts, kidney function and liver function
• Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria:

• Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
• Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
• Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C